ELI LILLY & Co — Director's Dealing 2025

Feb 12, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2025-02-10

Reporting Person: Van Naarden Jacob (EVP & Pres., Lilly Oncology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-10	Common Stock	A	6103.824	$868.88	Acquired	19561.985	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-10	Restricted Stock Unit	$	A	4108	Acquired	2026-02-01	Common Stock (4108)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4302	Indirect
Common Stock	4342	Indirect

Footnotes

F1: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.